Curi Bio said it has acquired Dana Solutions, a company that specializes in the application of artificial intelligence and machine learning to in vitro cell-based assays. The deal was for an undisclosed sum.
Seattle, WA-based Curi will gain access to Dana’s AI/ML-based platforms including PhenoLearn, a deep learning platform for modeling cell and tissue phenotypes; Pulse, an automated platform for contractility analysis of beating cardiomyocytes; and PhenoTox, a deep learning platform for predictive safety pharmacology.
Curi’s human iPSC-based platforms help drug developers build predictive and mature human iPSC tissues—especially for the discovery, safety testing, and efficacy testing of new therapeutics—with a focus on cardiac, skeletal muscle, and neuromuscular disease models. Curi seeks to de-risk and expedite the development of new drugs by providing human-relevant preclinical data and decreasing the industry’s dependence on animal models, which often fail to translate to humans.
“Curi Bio is developing human-relevant platforms integrating human cells, systems, and data to accelerate the discovery of new medicines,” Curi CEO Michael Cho. “With the acquisition of Dana’s AI/ML technologies for cell-based assays, Curi is now uniquely positioned to offer pharmaceutical companies an integrated platform leveraging predictive human iPSC-derived cells, tissue-specific biosystems, and AI/ML-enabled phenotypic data insights.”